期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 123, 期 7, 页码 2965-2968出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI67201
关键词
-
资金
- Adenoid Cystic Carcinoma Research Foundation
- Wellcome Trust [077012/Z/05/Z, WT088340MA]
- NIH National Institute of Dental and Craniofacial Research (NIDCR)
- NIH Office of Rare Diseases Research (ORDR) [U01DE019765]
- NIH National Cancer Institute MD Anderson Cancer Center Head and Neck Specialized Program of Research Excellence (SPORE) [P50 CA097007]
- National Research Council Canada
- EMBO Fellowship
- International Human Frontier Science Program Organization
Adenoid cystic carcinoma (ACC) is a rare malignancy that can occur in multiple organ sites and is primarily found in the salivary gland. While the identification of recurrent fusions of the MYB-NFIB genes have begun to shed light on the molecular underpinnings, little else is known about the molecular genetics of this frequently fatal cancer. We have undertaken exome sequencing in a series of 24 ACC to further delineate the genetics of the disease. We identified multiple mutated genes that, combined, implicate chromatin deregulation in half of cases. Further, mutations were identified in known cancer genes, including PIK3CA, ATM, CDKN2A, SF3B1, SUFU, TSC1, and CYLD. Mutations in NOTCH1/2 were identified in 3 cases, and we identify the negative NOTCH signaling regulator, SPEN, as a new cancer gene in ACC with mutations in 5 cases. Finally, the identification of 3 likely activating mutations in the tyrosine kinase receptor FGFR2, analogous to those reported in ovarian and endometrial carcinoma, point to potential therapeutic avenues for a subset of cases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据